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score. Results: Mean DMC per QoL was lowest in Pr, and highest in Hem cancers 
(ranged 60.1-195.1 TL/global QoL score) (Pr< Gy< CR≈Gas≈Br≈Lng≈H&N< Hem). QoL 
was lowest in Gy and highest in CR (ranged 53,1-65,2) (Gy< Lng< Pr< Br≈Hem≈H&NC). 
Total DMC ranged from 3124-13557 TL (Pr≈GY< Br< Gas≈CR< Lng≈H&N< Hem). 
Depending on the type of the cancer the association between DMC and QoL could 
be in different directions (the correlation between DMC and role functioning was 
positive in Gas, while it was negative in H&N cancer). ConClusions: For a fixed 
period of time the total DMC associated with the management of different types of 
cancers vary substantially. As expected the total cost does not however purchase 
equal amount of QoL for each type of cancer. For those cancers with higher DMC 
per QoL, we should consider implementing wider psychosocial support measures. 
Depending on the type of cancer DMC may reflect disease progression leading to 
decreased QoL, or it may reflect presence of an effective and aggressive manage-
ment leading to increased QoL.
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Cost-EffECtivENEss ModEl of PErtuzuMab iN CoMbiNatioN with 
trastuzuMab aNd doCEtaxEl CoMParEd with trastuzuMab iN 
CoMbiNatioN with doCEtaxEl for thE 1st liNE trEatMENt of hEr2+ 
MEtastatiC brEast CaNCEr iN ColoMbia
Saenz Ariza S.A.
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objeCtives: To evaluate the cost effectiveness of Pertuzumab plus Trastuzumab 
and docetaxel (PTD) vs. Trastuzumab and docetaxel (TD) for the first-line treat-
ment in patients with HER2+ metastatic breast cancer in Colombia. Methods: For 
the evaluation of the cost-effectiveness a health economic area under the curve 
model was developed. The model considers three health states: progression-free 
survival, disease progression and death. The proportion of patients in each health 
state were derived using patient level data from the CLEOPATRA trial like efficacy 
and safety results, with the exception where overall survival (OS) utilized data from 
longer term clinical registries. The primary model outcome is the ICER cost per QALY 
gained in the first-line PTD vs. TD. The following main model input data assump-
tions were applied for the base case analysis: Time horizon: 15 years; model cycle 
length: weekly; 3) reference prices for drugs in Colombia, except for Pertuzumab 
which was supplied by the manufacturer; 4) treatment duration: actual treatment 
duration from the CLEOPATRA study extrapolated using an exponential function; 
and 5) discount rates: annual rate of 3.0% for both, future costs and health ben-
efits. Results: The outcomes over a time horizon show an increase in mean OS 
time for patients assigned to the PTD group as compared to those in the TD of 0.72 
years. Mean QALYs are also higher in the PTD group than in the TD group 0.58 QALYs. 
The addition of Pertuzumab leads to higher total average treatment costs of $143.529 
dollars per patient compared to the TD group. These findings result in an ICER of 
$200.509 per life year gained and of $249.582 per QALY gained. ConClusions: 
When compared to commonly accepted cost-effectiveness thresholds, these results 
exceed commonly applied willingness-to-pay thresholds, but Pertuzumab becomes 
a therapeutic alternative that offers a better health outcome.
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with advaNCEd MEtastatiC MElaNoMa iN sPaiN
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objeCtives: To assess the cost-effectiveness of ipilimumab compared to dac-
arbazine as first-line treatment in patients with advanced metastatic mela-
noma. Methods: A three-state Markov (progression-free, progression and death) 
with three-week cycles model using the Spanish Healthcare System perspective was 
developed over a lifetime horizon. The clinical profile of ipilimumab (3 mg/kg) was 
obtained from a pooled dataset of chemotherapy naive patients from four phase 
II and phase III studies, and from the CA184-024 trial for dacarbazine. Parametric 
extrapolation methods were used to project survival over lifetime. Costs included 
were: drug acquisition (ex-factory price -7,5% mandatory rebate) and administra-
tion, medical/terminal care, and adverse events management. Unit costs were 
derived from Spanish health care cost databases (Euros, 2013). For drugs with a 
double-pricing system (like ipilimumab), costs were based upon the official noti-
fied prices in Spain. Costs and benefits were discounted at 3%. Utility values were 
taken from the CA184-024 trial. Univariate and probabilistic sensitivity analyses 
(PSA) were performed. Results: The life years (LYs) and quality-adjusted life years 
(QALYs) gained with ipilimumab as first-line treatment over dacarbazine were 2.01 
and 1.68, respectively. The incremental cost of using ipilimumab versus dacarbazine 
was 69,598 € . The incremental cost-effectiveness ratio (ICER) and the incremental 
cost-utility ratio (ICUR) were 34,566€ /LY gained and 41,459€ /QALY, respectively. PSA 
showed that ipilimumab is up to 100% and 90% likely to be cost-effective at the 
threshold established by the NICE for oncology drugs that meet ‘End-of-Life’ crite-
ria (50,000-62,000€ ) for ICER and ICUR, respectively. Additionally, at the threshold 
acceptable in Spain (30,000-45,000€ ) the likelihood of ipilimumab being cost-effec-
tive is up to 94% and 66% for ICER and ICUR, respectively. ConClusions: Results 
suggest that ipilimumab is a cost-effective alternative for previously untreated 
patients with advanced metastatic melanomain Spain.
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objeCtives: MR colonography may have potential as a colorectal cancer (CRC) 
screening tool since it has comparable test characteristics as colonoscopy but 
is less invasive. Furthermore, innovators in the field of MR technology are striv-
tests) were based on official reimbursed prices. Results: Out of 4,934 newly diag-
nosed breast cancer women, 27.5% (1,357) were appropriate for the test application. 
Only 35% of the women undertaken the oncotype test (N= 1,357) were found as high 
risk for recurrence (N= 475). The average total cost of chemotherapy treatment was 
estimated to € 8,271 from which more than 80% refer to pharmaceuticals. The total 
treatment cost for women who didn’t undertake the test reached to € 10.9 mil., 
while the relevant cost for women who undertook the test was estimated to € 8 mil.  
ConClusions: The introduction of Oncotype DX® to the Greek health care system 
had as a result annual cost savings of almost € 3 million and avoidance of unneces-
sary chemotherapy treatment (and associated complications) to more than 880 
women.
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objeCtives: The degree of benefit from colonoscopy in the prevention of colorectal 
cancer (CRC) is highly dependent on the quality of bowel cleansing. In a rand-
omized study of patients undergoing screening colonoscopy in Germany (MODEC), 
2L polyethylene glycol with electrolytes + ascorbate components (PEG+ASC) resulted 
in numerically higher overall polyp/adenoma detection rates (PDR/ADR) and sig-
nificantly higher right-sided PDR/ADR than sodium picosulfate/magnesium citrate 
(NaPic/MgCit), together with better bowel cleansing. The objective of the model 
was to examine the socioeconomic impact of bowel cleansing quality on the effec-
tiveness of CRC screening in the eligible German population. Methods: A cost-
consequence model was constructed to compare the total cost of colonoscopy and 
treatment of subsequent CRC over a 10-year period in a cohort of 10,000 patients 
aged ≥ 55 years receiving 2L PEG+ASC or NaPic/MgCit prior to colonoscopy. The 
rates of successful bowel cleansing, completed colonoscopies, and PDR/ADR were 
obtained from the MODEC study. Published rates of surveillance colonoscopy, associ-
ated costs and health care resource utilization in Germany were used, with costs 
inflated to 2013 prices. Results: The model predicts that the use of 2L PEG+ASC 
versus NaPic/MgCit increases the average per patient cost associated with colonos-
copy by € 67. However, better bowel cleansing and numerically higher overall PDR/
ADR achieved using 2L PEG+ASC rather than NaPic/MgCit avoids progression to CRC 
in 166 patients, due to early detection, equating to an average per patient saving in 
CRC treatment costs of € 488. The model shows that the use of 2L PEG+ASC versus 
NaPic/MgCit at screening/surveillance colonoscopy leads to an average overall cost 
saving of € 420 per patient over 10 years. ConClusions: Modeling of long-term 
outcomes shows that using an effective bowel cleansing preparation in CRC screen-
ing may reduce the number of patients developing CRC, and may lead to reduced 
CRC treatment costs.
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objeCtives: The objective of the study was to estimate the potential cost and epi-
demiological impact of a Human Papillomavirus (HPV) mass vaccination in Romania 
for the two available vaccines in the Romania: AS04 adjuvanted HPV16/18 vac-
cine (AS04V) and the HPV6/11/16/18 vaccine (QV). Methods: We applied, to the 
Romanian settings, a population steady state model previously published with a 
one year time horizon estimating the effect (cases and costs) of a vaccination pro-
gramme. The number of cases and costs (in RON – Romanian National Currency) 
were collected from the hospitalization Diagnosis Related Group database for the 
year 2012. cervical cancer (CC) and genital warts (GW) were considered. Vaccine 
effectiveness was approximated by weighting vaccine-type and non-vaccine-type 
efficacy with HPV distribution reported for GW (literature) and CC (HPV Centre) for 
each vaccine. One way sensitivity analysis was conducted on key input param-
eters. Results: HPV vaccination would save17,706,490 RON with AS04V and 
16,432,592 RON with QV. An additional 820 CC-related hospitalisations amounting 
to a cost difference of 1,273,898 RON was estimated in favour of the AS04V. A total 
of 205 cases of GW prevented and 153,395 RON associated costs were estimated in 
favour of the QV. The total cost difference amounted to 1,120,503 RON. Robustness of 
the results was confirmed by sensitivity analyses”. ConClusions: Implementing 
the AS04V would result in > 1 million RON saved versus the QV mainly due to a dif-
ference of extra 820 CC cases prevented that completely offsets the benefit associ-
ated with the prevention of GW. The observed difference is mainly due to higher 
protection associated with non-vaccine types for AS04V.
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assoCiatioN of hEalth CarE Cost with quality of lifE for various 
tyPEs of CaNCErs
Hayran M., Yuce D., Huseyin B., Esin E., Kilickap S., Erman M., Celik I.
Hacettepe University, Ankara, Turkey
objeCtives: The new cancer treatment modalities are improving survival rates 
today and one of the main outcomes is the improved health related quality of 
life (QoL). Prolonged survival also increases the financial burden of cancer care on 
health care systems. In this study we aimed to analyze the associations between 
QoL and direct health care costs in different types of cancers. Methods: We evalu-
ated QoL (EORTC QLQ-C30) and direct medical costs (DMC) in 350 patients with lung 
(Lng), breast (Br), hematological (Hem), head and neck (H&N), colorectal (CR), gastric 
(Gas), gynecological (Gy), and prostate (Pr) cancers. The DMC data of each patient in 
the following 3-month period after QoL assessment was obtained from the hospi-
tal finance department database. DMC per QoL point was calculated by DMC/QoL 
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objeCtives: To estimate the cost-effectiveness of nab-paclitaxel+gemcitabine (Npg) 
versus gemcitabine (Gem) alone for the first-line treatment of metastatic pancreatic 
cancer in Greece from a National Health System perspective Methods: A Markov 
model was developed, included several stages such as: “pre-progression on first-
line treatment”, “pre-progression off first-line treatment”, “post progression”, “four 
weeks to death” and “death”. Data from the MPACT trial were used to estimate overall 
survival (Life-Years- (LYs)) and adverse events. The prices of drugs used in the model 
are publicly available for all hospitals in Greece. Cost assigned in each health state 
reflected: drugs, adverse events, monitoring, administration and palliative care. Utility 
values were obtained from the international literature to estimate Quality-Adjusted-
Life-Years (QALYs). Costs and health gains were discounted at 3.5% per annum. A 
probabilistic sensitivity analysis was also conducted to construct confidence inter-
vals (CI). Results: The mean number of QALYs was 0.71 (95%CI: 0.66–0.78) and 0.56 
(95%CI: 0.52–0.60) for Npg and Gem, respectively, giving an incremental gain of 0.15 
(95%CI: 0.08-0.25) QALYs in favour of Npg. The mean cost of therapy per patient was 
estimated at € 15,628 (95%CI: € 14,377- € 17,027) and € 8,284 (95%CI: € 7,455-€ 9,112) for 
Npg and Gem, respectively. The incremental cost per LY gained with Npg was esti-
mated at € 37,007 and the incremental cost per QALY gained at € 47,120. The probability 
for Npg to be cost-effective at a threshold three times the per capita income (€ 60,000 
per QALY) was 82%. ConClusions: The severity of pancreatic cancer, in combination 
with the limited number of effective treatments, results in a high level of unmet need. 
If the societal willingness-to-pay threshold for an additional QALY is relatively higher 
for patients with short life expectancy or for diseases with a relatively higher burden, 
the combination of nab-paclitaxel+gemcitabine could be considered a cost-effective 
choice compared with gemcitabine alone in Greece.
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objeCtives: To compare the cost-effectiveness of panitumumab plus mFOLFOX6 
(oxaliplatin, 5-fluorouracil and leucovorin) versus bevacizumab plus mFOLFOX6 
as first-line treatment for patients with wild-type RASmetastatic colorectal cancer 
(mCRC). Methods: Using a French health collective perspective, a lifetime Markov 
model was constructed, with health states related to first-line therapy (progression-
free), disease progression with/without subsequent active treatment, resection of 
metastases, disease-free after successful resection, and death. Transitions to disease 
progression and death were estimated using parametric survival analyses of patient-
level progression-free (PFS) and overall (OS) survival from the only head-to-head clini-
cal trial of panitumumab versus bevacizumab in mCRC (PEAK). Additional data from 
PEAK informed the amount of each drug consumed, duration of therapy, subsequent 
therapy use, and toxicities related to mCRC treatment. Literature and French public 
data sources were used to estimate unit costs associated with treatment, duration 
of subsequent active therapies, and survival post-resection. Patient-level data from 
panitumumab trials in the first-, second-, and third-line settings were used to deter-
mine utility weights. One-way and probabilistic sensitivity analyses were performed. 
Scenario analyses examined modelling of PFS and OS using observational survival 
data and PEAK hazard ratios. Results: Based on the better efficacy outcomes for 
patients with wild-type RASmCRC who received panitumumab plus mFOLFOX6 ver-
sus bevacizumab plus mFOLFOX6 in PEAK, the incremental cost per life-year gained 
was estimated to be € 26,918, and the incremental cost per quality-adjusted life year 
(QALY) gained was estimated to be € 36,577. Sensitivity and scenario analyses indi-
cate the model is robust to alternative parameters and assumptions. ConClusions: 
Panitumumab plus mFOLFOX6 can be considered cost-effective in first-line treatment 
of patients with wild-type RAS mCRC.
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objeCtives: To assess the cost-utility of pazopanib vs. sunitinib as first-line treat-
ment of mRCC from the Spanish National Healthcare perspective. Methods: A 
published partitioned-survival analysis model was used to estimate the incremental 
cost-utility ratio (ICUR) of pazopanib vs. sunitinib. Progression free survival (PFS) and 
overall survival (OS) data from COMPARZ (NCT00720941), a non-inferiority head to 
head phase III-trial of sunitinib vs. pazopanib, were used to generate survival func-
tions up to overall time horizon. Patients can be in one of three mutually exclusive 
health states over time: alive and no progression, alive with progression and dead. 
Utilities values were obtained from PISCES trial (NCT01064310) and adjusted tak-
ing into account the different treatment schedules (sunitinib-cycles: 4 weeks-on 
plus2 weeks-off; pazopanib 800 mg/day). Health resource utilization was collected 
using individual patient data from COMPARZ trial and their corresponding unit 
costs were retrieved from published Spanish tariffs. Base-case analysis considered: 
ing to develop a targeted contrast agent that specifically detects adenomas at 
increased risk of progressing to CRC. This might even further raise the potential 
of MR colonography. We explored the potential of conventional and targeted MR 
colonography in terms of (cost-) effectiveness using the ASCCA model. Methods: 
Thirteen screening strategies were evaluated, differing in primary screening 
instrument and number of screening rounds. The strategies under consideration 
were conventional and targeted MR colonography, colonoscopy and CT colonog-
raphy with two, three and four screening rounds at a ten year screening interval. 
Furthermore, eleven rounds of biennial faecal immunochemical test (FIT) screen-
ing were considered. Each strategy was evaluated assuming realistic and perfect 
participation rates. Incremental costs and effects were estimated from a societal 
perspective. Results: All screening strategies were cost-effective compared to 
no screening. For conventional MR colonography, the ICER ranged between € 1,271/
LYG to € 3,003/LYG for two to four screening rounds at 34% participation per round. 
For 62% and 100% participation, the ICER ranged from respectively € 1,576/LYG to 
€ 3,777/LYG and € 1,971/LYG to € 4,577/LYG. However, conventional MR colonography 
screening was more expensive than other screening strategies at comparable 
LYG, for all participation rates. Targeted MR colonography was only slightly more 
effective than conventional MR colonography but considerably more costly, even 
under the most favourable assumptions regarding test characteristics and costs 
per test. ConClusions: This is the first study to evaluate the cost-effectiveness 
of MR colonography screening for CRC. Although conventional and targeted MR 
colonography are cost-effective compared to no screening, at present they cannot 
compete with more established screening tests because of the high costs per test.
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objeCtives: To assess the cost-effectiveness of Abiraterone Acetate plus 
Prednisone (A-P) compared with Cabazitaxel plus Prednisone (C-P) in Panama, 
in patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that 
have failed to chemotherapy with Docetaxel. Methods: A three-health state 
cohort simulation Markov Model (progression-free, post-progression and death) 
was developed based on overall and progression free survival data. The time frame 
was 10 years. The perspective was that of the Public System of Health of Panama. 
The health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life 
Years (LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and 
TROPIC for C-P). Utilities for health states and negative utilities for adverse events 
were estimated based on quality of life endpoints of the COU-AA-301 trial. The 
base year was 2012. All costs are presented in United States Dollars (USD). Costs 
and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis was 
performed to evaluate uncertainty surrounding the parameters. Results: A-P 
resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: 
USD 76.179 for A-P and USD 86.286 for C-P. The results of the probabilistic sensitiv-
ity analysis showed that, when compared with C-Z, A-P was found dominant (asso-
ciated with reduced costs and increased QALYs) in the majority of the iterations. 
A-P had a 73% probability of being cost effective, independent of the willingness 
to pay, when compared to C-P. When the willingness to pay increases, A-P is more 
likely to become cost effective. ConClusions: A-P can be considered dominant 
(cost-saving), when compared with C-P, in patients with Metastatic Castration-
Resistant Prostate Cancer that have failed to chemotherapy with Docetaxel, from 
the perspective of the Public System of Health of Panama.
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objeCtives: This study evaluated the cost-effectiveness of everolimus plus exemes-
tane (EVE+EXE) versus exemestane (EXE) and fulvestrant (FUL) in the treatment of 
postmenopausal women with ER+ HER2- metastatic breast cancer in the United 
Kingdom (UK) from a societal perspective. Methods: A partitioned survival model 
was developed to compare treatment with EVE+EXE versus EXE and FUL over a 
10-year time horizon. Progression-free survival and overall survival for EVE+EXE 
and EXE were estimated from the BOLERO-2 trial. Log-logistics functions were used 
to extrapolate trial data beyond the follow-up period. In the absence of head-to-
head evidence vs. FUL an indirect treatment comparison was conducted using a 
Bayesian fixed effect model. Background health state and terminal care resource 
use were derived from NICE Clinical Guideline 81. Drug costs were taken from the 
British National Formulary. Productivity loss, defined as working days lost due to 
disease, was included in the analysis. Utilities from published sources were com-
bined with trial data to calculate quality-adjusted life years (QALYs) for the model 
health state. Results: EVE+EXE led to an incremental gain in life years of 0.20 vs. 
EXE and 0.19 vs. FUL. The incremental QALY gain was 0.31 vs. EXE and 0.27 vs. FUL. 
The cost of lost productivity was £66,163 in the EVE+EXE compared to £75,067 in the 
EXE arm and £73,434 in the FUL arm. The incremental cost per QALY was £27,644 
vs. EXE and £14,030 vs. FUL. Probabilistic sensitivity analysis demonstrated that, at 
a threshold of £30,000 per QALY gained, EVE+EXE had a 51.6% likelihood of being 
cost-effective vs. EXE and 59.0% vs. FUL. ConClusions: Patients receiving EVE+EXE 
experienced an improvement in survival which translated into health gains in terms 
of both LYs and QALYs. EVE+EXE was associated with savings in productivity costs 
compared to both EXE and FUL.
